Measurement of 1,5-anhydroglucitol in blood and saliva: From non-targeted metabolomics to biochemical assay

Anna Halama, Michal Kulinski, Sara Abdulkader, Noothan Satheesh, Abdul Badi Abou-Samra, Karsten Suhre, Ramzi M. Mohammad

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1,5-anhydro-d-glucitol (1,5-AG) in saliva as a diabetes biomarker. The Glycomark™ assay kit is FDA approved for 1,5-AG measurement in blood. Here we evaluated its applicability for 1,5-AG quantification in saliva. Methods: Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona+ clinical chemistry analyser. We then used this set-up to analyse 82 paired blood and saliva samples from a diabetes case-control study, for which broad mass spectrometry-based characterization of the blood and saliva metabolome was also available. Osmolality was measured to account for potential variability in saliva samples. Results: The technical variability of the read-outs for the pooled saliva samples (CV = 2.05 %) was comparable to that obtained with manufacturer-provided blood surrogate quality controls (CV = 1.38-1.8 %). We found a high correlation between Glycomark assay and mass spectrometry measurements of serum 1,5-AG (r2 = 0.902), showing reproducibility of the non-targeted metabolomics results. The significant correlation between the osmolality measurements performed at two independent platforms with the time interval of 2 years (r2 = 0.887), also indicates the sample integrity. The assay read-out for saliva was not correlated with the mass spectrometry-based 1,5-AG saliva measurements. Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read-outs with galactose. Conclusions: Glycomark™ assay read-outs for saliva were stable and replicable. However, the signal was dominated by galactose, which is biochemically similar to 1,5-AG and absent in blood. Adapting the 1,5-AG kit for saliva analysis will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for glucose depletion from blood samples.

Original languageEnglish
Article number140
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Metabolomics
Saliva
Assays
Blood
Medical problems
Galactose
Mass spectrometry
Mass Spectrometry
Metabolome
Sorbitol
Biomarkers
1,5-anhydroglucitol
Osmolar Concentration
Quality control
Blood Glucose
Screening
Clinical Chemistry
Testing
Quality Control
Case-Control Studies

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Measurement of 1,5-anhydroglucitol in blood and saliva : From non-targeted metabolomics to biochemical assay. / Halama, Anna; Kulinski, Michal; Abdulkader, Sara; Satheesh, Noothan; Abou-Samra, Abdul Badi; Suhre, Karsten; Mohammad, Ramzi M.

In: Journal of Translational Medicine, Vol. 14, No. 1, 140, 2016.

Research output: Contribution to journalArticle

@article{de7c44c780bd40978c6fa855343cc169,
title = "Measurement of 1,5-anhydroglucitol in blood and saliva: From non-targeted metabolomics to biochemical assay",
abstract = "Background: Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1,5-anhydro-d-glucitol (1,5-AG) in saliva as a diabetes biomarker. The Glycomark™ assay kit is FDA approved for 1,5-AG measurement in blood. Here we evaluated its applicability for 1,5-AG quantification in saliva. Methods: Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona+ clinical chemistry analyser. We then used this set-up to analyse 82 paired blood and saliva samples from a diabetes case-control study, for which broad mass spectrometry-based characterization of the blood and saliva metabolome was also available. Osmolality was measured to account for potential variability in saliva samples. Results: The technical variability of the read-outs for the pooled saliva samples (CV = 2.05 {\%}) was comparable to that obtained with manufacturer-provided blood surrogate quality controls (CV = 1.38-1.8 {\%}). We found a high correlation between Glycomark assay and mass spectrometry measurements of serum 1,5-AG (r2 = 0.902), showing reproducibility of the non-targeted metabolomics results. The significant correlation between the osmolality measurements performed at two independent platforms with the time interval of 2 years (r2 = 0.887), also indicates the sample integrity. The assay read-out for saliva was not correlated with the mass spectrometry-based 1,5-AG saliva measurements. Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read-outs with galactose. Conclusions: Glycomark™ assay read-outs for saliva were stable and replicable. However, the signal was dominated by galactose, which is biochemically similar to 1,5-AG and absent in blood. Adapting the 1,5-AG kit for saliva analysis will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for glucose depletion from blood samples.",
author = "Anna Halama and Michal Kulinski and Sara Abdulkader and Noothan Satheesh and Abou-Samra, {Abdul Badi} and Karsten Suhre and Mohammad, {Ramzi M.}",
year = "2016",
doi = "10.1186/s12967-016-0897-6",
language = "English",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Measurement of 1,5-anhydroglucitol in blood and saliva

T2 - From non-targeted metabolomics to biochemical assay

AU - Halama, Anna

AU - Kulinski, Michal

AU - Abdulkader, Sara

AU - Satheesh, Noothan

AU - Abou-Samra, Abdul Badi

AU - Suhre, Karsten

AU - Mohammad, Ramzi M.

PY - 2016

Y1 - 2016

N2 - Background: Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1,5-anhydro-d-glucitol (1,5-AG) in saliva as a diabetes biomarker. The Glycomark™ assay kit is FDA approved for 1,5-AG measurement in blood. Here we evaluated its applicability for 1,5-AG quantification in saliva. Methods: Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona+ clinical chemistry analyser. We then used this set-up to analyse 82 paired blood and saliva samples from a diabetes case-control study, for which broad mass spectrometry-based characterization of the blood and saliva metabolome was also available. Osmolality was measured to account for potential variability in saliva samples. Results: The technical variability of the read-outs for the pooled saliva samples (CV = 2.05 %) was comparable to that obtained with manufacturer-provided blood surrogate quality controls (CV = 1.38-1.8 %). We found a high correlation between Glycomark assay and mass spectrometry measurements of serum 1,5-AG (r2 = 0.902), showing reproducibility of the non-targeted metabolomics results. The significant correlation between the osmolality measurements performed at two independent platforms with the time interval of 2 years (r2 = 0.887), also indicates the sample integrity. The assay read-out for saliva was not correlated with the mass spectrometry-based 1,5-AG saliva measurements. Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read-outs with galactose. Conclusions: Glycomark™ assay read-outs for saliva were stable and replicable. However, the signal was dominated by galactose, which is biochemically similar to 1,5-AG and absent in blood. Adapting the 1,5-AG kit for saliva analysis will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for glucose depletion from blood samples.

AB - Background: Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1,5-anhydro-d-glucitol (1,5-AG) in saliva as a diabetes biomarker. The Glycomark™ assay kit is FDA approved for 1,5-AG measurement in blood. Here we evaluated its applicability for 1,5-AG quantification in saliva. Methods: Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona+ clinical chemistry analyser. We then used this set-up to analyse 82 paired blood and saliva samples from a diabetes case-control study, for which broad mass spectrometry-based characterization of the blood and saliva metabolome was also available. Osmolality was measured to account for potential variability in saliva samples. Results: The technical variability of the read-outs for the pooled saliva samples (CV = 2.05 %) was comparable to that obtained with manufacturer-provided blood surrogate quality controls (CV = 1.38-1.8 %). We found a high correlation between Glycomark assay and mass spectrometry measurements of serum 1,5-AG (r2 = 0.902), showing reproducibility of the non-targeted metabolomics results. The significant correlation between the osmolality measurements performed at two independent platforms with the time interval of 2 years (r2 = 0.887), also indicates the sample integrity. The assay read-out for saliva was not correlated with the mass spectrometry-based 1,5-AG saliva measurements. Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read-outs with galactose. Conclusions: Glycomark™ assay read-outs for saliva were stable and replicable. However, the signal was dominated by galactose, which is biochemically similar to 1,5-AG and absent in blood. Adapting the 1,5-AG kit for saliva analysis will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for glucose depletion from blood samples.

UR - http://www.scopus.com/inward/record.url?scp=85007614151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007614151&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-0897-6

DO - 10.1186/s12967-016-0897-6

M3 - Article

C2 - 27188855

AN - SCOPUS:85007614151

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 140

ER -